Key terms
About ARQT
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARQT news
Apr 30
2:50am ET
Buy Rating Reiterated for ARQT Amidst Strong Zoryve Performance and Market Resilience
Apr 22
2:50am ET
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
Apr 12
6:40am ET
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
Apr 01
7:18am ET
Sol-Gel Technologies collaboration partner first-to-file ANDA generic to Zoryve
Mar 19
1:50am ET
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Mar 13
2:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Mar 11
8:11am ET
Arcutis Biotherapeutics appoints Todd Tucker as CHRO
Mar 10
4:09pm ET
Arcutis presents late-breaking data from INTEGUMENT-PED Phase 3 trial
Feb 29
6:43am ET
Arcutis Biotherapeutics 15.79M share Spot Secondary priced at $9.50
Feb 28
4:05pm ET
Arcutis gets $25M upfront in partnership deal with Japan’s Sato for roflumilast
Feb 28
8:49am ET
Arcutis Biotherapeutics price target raised to $16 from $8 at Needham
Feb 28
7:22am ET
Arcutis Biotherapeutics price target raised to $17 from $16 at Mizuho
Feb 27
8:10pm ET
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Arcutis Biotherapeutics (ARQT)
Feb 27
6:25pm ET
Arcutis Biotherapeutics (ARQT) Gets a Hold from JonesTrading
Feb 27
4:40pm ET
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)
Feb 27
12:35pm ET
Buy Rating Affirmed for Arcutis Biotherapeutics as Zoryve Sales Surge and Market Position Strengthens
Feb 27
5:59am ET
Arcutis Biotherapeutics reports Q4 EPS (72c), consensus (77c)
Feb 23
6:55am ET
Arcutis Biotherapeutics price target raised to $16 from $8 at Mizuho
Feb 15
4:34pm ET
Arcutis Biotherapeutics Launches Stock Option Exchange Program
Feb 10
11:26am ET
Short Report: Bears squeeze MicroStrategy as shares track bitcoin higher
Feb 09
1:18am ET
Buy Rating for Arcutis Biotherapeutics: Strong Market Protection and Anticipated Legal Defense Amid Generic Competition
Feb 07
10:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Walgreens Boots Alliance (WBA) and Twist Bioscience (TWST)
Jan 31
5:23pm ET
Arcutis Biotherapeutics files $300M mixed securities shelf
No recent press releases are available for ARQT
ARQT Financials
Key terms
Ad Feedback
ARQT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARQT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
